T
he genus Mycobacterium has undergone tremendous taxonomic revision in recent decades. There are currently 170 recognized species (http://www.bacterio.net/mycobacterium.html; accessed 20 February 2014) with a wide range of pathogenic potential from benign environmental contaminants to the pathogenic Mycobacterium tuberculosis complex, which was estimated to be responsible for 9 million cases of disease and 1.5 million deaths worldwide in 2013 (1) . While M. tuberculosis remains the most clinically significant species and public health threat within this genus, many non-tuberculosis mycobacteria (NTM) are wellestablished pathogens and may be increasing in prevalence in part due to increased numbers of immunocompromised individuals as well as to the increasing prevalence of medical hardware and indwelling devices (2) .
When mycobacteria are recovered from clinical specimens, establishment of a species-or complex-level identification is critical to distinguish pathogenic species from common environmental contaminants (such as Mycobacterium gordonae) and to guide antimicrobial therapy, when indicated. Species-level identification has classically relied on a variety of characteristics and methodologies, including growth rate, pigmentation, enzymatic properties (3, 4) , and high-performance liquid chromatography (HPLC), which generates species-or complex-specific mycolic acid profiles (5) . In addition, molecular assays, including those using nucleic acid probes, have been used for identification of some common Mycobacterium spp., including M. tuberculosis and Mycobacterium avium complex (6) . DNA sequencing of 16S rRNA, rpoB, and hsp65 genes is widely considered the gold standard for identification (7) . However, these methods can be time-consuming and expensive, can require specific equipment and expertise, and often have limited availability outside reference laboratories.
Recently, matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has been used to provide relatively rapid, inexpensive, and accurate identification of a variety of microorganisms, including Mycobacterium spp. (8) (9) (10) (11) . However, unlike most bacteria, which can be directly spotted onto a MALDI-TOF target plate, mycobacteria require inactivation and extraction steps prior to analysis, both for biosafety and for access to proteins in the cells. The inactivation step is commonly performed with heat-killing and/or ethanol (8) . For optimal results, the mycobacterial protein must be extracted from the cells, most commonly by silica bead beating, given the poorly permeable and mycolic acid-rich cell wall. Each of these steps and protocols, in addition to the breadth and depth of the MALDI-TOF MS refer-ence databases, may introduce assay variability and influence the analytical performance characteristics of the method.
There are two commercially available MALDI-TOF MS platforms: the Bruker Biotyper (Bruker, Billerica, MA) and the bioMérieux Vitek MS (bioMérieux, Durham, NC). Our objective was to compare the contemporary databases and specimen preparation methods recommended for the Bruker Biotyper to those recommended for the Vitek MS. We compared solid-medium types for organism cultivation prior to MS analysis, extraction methods, and the reliability and accuracy of Mycobacterium species identification.
MATERIALS AND METHODS
Clinical isolates and identification. This was an analysis of 167 banked isolates of Mycobacterium spp. Ten isolates were used for an initial comparison of medium types and extraction methods, while 157 isolates were used to assess the analytical performance characteristics of each method. All isolates were recovered from clinical specimens submitted to the Barnes-Jewish Hospital microbiology laboratory between 2009 and 2014. M. tuberculosis complex, M. avium complex, Mycobacterium kansasii, and M. gordonae were identified by a chemiluminescent DNA probe hybridization assay (AccuProbe; Hologic, Inc., Bedford, MA). All other mycobacterial species were identified by the Wisconsin State Laboratory of Hygiene or the Oklahoma State Department of Public Health by mycolic acid profile analysis (using HPLC) and/or DNA sequencing of the 16S rRNA and rpoB genes.
Culture conditions. Unless indicated otherwise, all isolates were cultured on Middlebrook 7H10 agar (7H10; Remel, Lenexa, KS) at 35°C without supplemental CO 2 . Mycobacterium marinum and Mycobacterium haemophilum were grown at 30°C. M. haemophilum was cultured on chocolate agar. To compare the effects of medium types, a subset of isolates were cultured on both 7H10 and Löwenstein-Jensen (LJ) agar at 35°C.
Experimental design. To enable direct comparison of the Biotyper and Vitek MS mycobacterial identification methods, all extractions were performed for both assays from isolates grown on identical culture media at the same time. Similar biomasses, consisting of heaping inocula on a 1-l disposable loop (Nunc, Roskilde, Denmark), were used for the two assays.
Comparison of solid media and extraction methods. We selected a panel of 10 commonly isolated NTM isolates to compare the Biotyper and Vitek MS protein extraction methods using both 7H10 and LJ solid media. This collection of isolates included four rapidly growing NTM species (two Mycobacterium abscessus, one Mycobacterium chelonae, and one Mycobacterium fortuitum) and six slowly growing NTM species (two each of M. avium complex, M. gordonae, and M. kansasii). For this pilot study, scores and confidence values of Ն2.0 and Ն90% were set as the diagnostic thresholds for the Biotyper and Vitek MS, respectively. Extractions were done in duplicate, with each extraction method applied once per target plate in each of two independent experiments, resulting in 40 total results per MALDI-TOF MS platform.
Comprehensive evaluation of diverse mycobacterial isolates. For the comparisons among the 157 Mycobacterium spp., a single extraction was performed and the extracted material was spotted in duplicate in each of three independent experiments. Two independent operators tested each isolate.
Biotyper specimen preparation method. Samples were extracted according to the Bruker MALDI Biotyper standard operating procedure (revision 2 January 2013). Briefly, mycobacterial isolates were suspended in 300 l H 2 O and then heat inactivated for 30 min in a 95°C heat block. Samples were centrifuged, resuspended in 70% ethyl alcohol (EtOH), washed in H 2 O, and then resuspended in 50 l H 2 O prior to incubation for 10 min at 95°C. Samples were then washed in 100% EtOH, dried, and then subjected to vortex mixing for 1 min with 0.5-mm-diameter glass beads (VWR, Radnor, PA) and 20 l acetonitrile. After bead beating specimens horizontally by the use of a vortex adaptor, 20 l of 70% formic acid was added. Samples were then centrifuged, and 1 l of supernatant was spotted per target. After drying, 1 l of HCCA (alpha-cyano-4-hydroxycinnamic acid; Bruker) matrix solution was overlaid. Bacterial Test Standard (Bruker) was direct spotted onto each target as a calibrant and control. All targets were analyzed within 3 h of the spotting procedure. Biotyper Real Time Classification software version 3.1 and Biotyper Mycobacteria Library 1.0 were used for analysis. All samples were analyzed exclusively in automatic mode. The Biotyper employs a laser frequency of 60 Hz and records mass spectra from 2,000 to 20,000 Da. Each spot was sampled in nine different areas with 40 shots per sampling area. The resulting spectra were flattened, compared to a database, and analyzed to produce a logarithmic score of from 0 to 3.0. Per the manufacturer, scores of Ն2.0 are considered reliable for species-level identification, scores of 1.7 to 1.9 are accurate for genus-level identification, and scores of Ͻ1.7 are unreliable (9) .
Vitek MS extraction method. Samples were extracted according to the Mycobacteria Test protocol (bioMérieux). Briefly, a suspension of mycobacteria was mixed with silica beads and 70% EtOH and then mechanically disrupted by vortex mixing for 10 to 15 min at 3,000 rpm (Vortex Genie 2 [Scientific Industries] with MoBio Vortex Adaptor). After bead beating was performed, samples were incubated for 10 min at room temperature and then the supernatant was transferred to a new tube. Samples were then pelleted, dried, and resuspended in 10 l of 70% formic acid. The suspension was incubated for 2 to 5 min, and then 10 l acetonitrile was added. The samples were then centrifuged, and 1 l of supernatant was added per target spot. After the extract was dried, 1 l of Vitek MS-CHCA Matrix (bioMérieux) was overlaid and allowed to dry completely. An Escherichia coli reference strain (ATCC 8739) was directly spotted on each acquisition group on each slide as a calibrant and control per manufacturer protocols. All slides were run within 3 h of organism application. All samples were run exclusively in automatic mode. Spectra were generated on the Vitek MS, and the resulting spectra were simultaneously analyzed using both the Saramis and v3.0 software. The v3.0 spectra were analyzed using SpectraIdentifier v2.1.0, a research and development tool. The v3.0 software is currently under development and is not yet commercially available.
The Vitek MS employs a laser frequency of 50 Hz and records mass spectra of from 2,000 to 20,000 Da. Each spot was pulsed 100 times, and each generated a unique mass spectrum, and the mass spectra were summed into a single spectrum that then underwent "mass binning" (12) . This resulted in an isolate identification with a confidence value of from 0% to 99.99% for Saramis and 0% to 99.9% for v3.0. Results from lowquality or absent spectra receive a classification of "no identification" (12) .
Discrepant resolution. If the isolate identification obtained as part of routine testing (see the description of culture conditions and identification above) was identical to the identification generated by all three of the MALDI-TOF MS methods, the result was considered to be correct without the need for additional testing. For any isolates where discrepancies were observed, the isolate was identified by rpoB and/or 16S rRNA gene sequencing for definitive identification.
Assessment of organism inactivation following specimen preparation. A M. tuberculosis control strain (ATCC 25177) was used to assess the ability of the Biotyper and Vitek MS specimen preparation protocols to inactivate this species. Each extraction method was performed in triplicate in each of two independent experiments. For the Bruker extraction, samples were inactivated for 30 min at 95°C followed by treatment with 70% EtOH. After the EtOH was decanted, the pellet was resuspended in 200 l sterile H 2 O and the entire volume was used to inoculate a mycobacterial growth indicator tube (MGIT) with polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azlocillin (PANTA) antibiotic (BD, Franklin Lakes, NJ). For the Vitek MS extraction, M. tuberculosis was inactivated with 70% EtOH and the cell pellet was resuspended in 100 l of sterile H 2 O and was used to inoculate a MGIT tube. For both methods, M. tuberculosis inactivation was confirmed by incubation of the MGIT for 6 weeks at 35°C in a Bactec MGIT mycobacterial detection system.
Statistical analysis. The Wilcoxon matched-pair signed-rank test was used to analyze the impact of the extraction method on scores. Fisher's exact test was used to compare the effects of the extraction methods on the frequencies of samples without identification. To compare the numbers of repeats needed to obtain an identification, a chi-square test comparing the three methods with the four outcomes (identification by the first, second, or third experiment or no identification) was performed. A chi-square test for trend (Cochran-Armitage test for trend) was then used for pairwise analysis. A P value of less than 0.05 was considered significant. Data were analyzed with Prism 6 (GraphPad Software Inc., La Jolla, CA) and SPSS Version 22 (IBM, Armonk, NY).
RESULTS
Comparison of solid media. We compared NTM identification using isolates obtained from 7H10 and LJ solid media and the Biotyper, Saramis, and Vitek MS v3.0 methods on a panel of 10 NTM isolates. All 10 isolates were correctly identified in at least one of two replicates in at least one of two independent experiments, while no isolates were misidentified above the given thresholds (score of Ն2.0 for Biotyper and confidence value of Ն90% for Saramis and v3.0). Using the Biotyper, 37/40 samples from 7H10 and 33/40 from LJ agar were correctly identified (Table  1) . Using the Saramis database, 37/40 and 31/40 were correctly identified from 7H10 and LJ agar, respectively. Finally, using the Vitek MS v3.0 database, 39/40 and 35/40 samples were correctly identified from 7H10 and LJ, respectively. The differences in the frequencies of correct identifications between 7H10 and LJ for the Biotyper, Saramis, and v3.0 methods individually were not significantly different, but the cumulative identification rate from 7H10 (113/120; 94.2%) was significantly better than that seen with LJ (99/120; 82.5%) overall (P ϭ 0.008).
Comparison of extraction methods. Next, we evaluated whether the method of extraction of mycobacteria grown on 7H10 medium impacted the reliability of identification. For samples analyzed by the Biotyper, 35/40 isolates extracted with the Vitek MS method and 36/40 extracted with the Biotyper method yielded an identification (P ϭ 0.99). Application of the Vitek MS extraction method resulted in Biotyper scores significantly lower than those obtained with the same samples extracted with the Biotyper extraction method (median difference, 0.16; P Ͻ 0.0001) (Fig. 1A) . For samples analyzed with Saramis, there were signifi- (Fig. 1B) . For samples analyzed by Vitek MS v3.0, 35/40 spots generated an identification with the Vitek MS extraction and 30/40 gave an identification with the Biotyper extraction (P Ͻ 0.25). The Vitek MS v3.0 was relatively insensitive to the extraction method (median difference, 0.01%; P Ͻ 0.024) (Fig. 1C) .
Comparison of the Biotyper, Saramis, and Vitek MS v3.0 methods for mycobacterial identification. We assessed the performance of the Biotyper, Saramis, and Vitek MS v3.0 for the identification of 157 mycobacterial isolates cultivated on 7H10 ( Table 2 ). The isolates comprise 22 different mycobacterial complexes or species, including 9 complexes or species of rapid-growing NTM (n ϭ 72), 12 complexes or species of slow-growing NTM (n ϭ 69), and M. tuberculosis (n ϭ 16).
For the Biotyper, 2/157 (1.3%) isolates were not identified at any score in any of the three independent extractions (Table 3) . Using a modified score threshold of Ն1.5, 147/157 (93.6%) were correctly identified, 3/157 (1.9%) were incorrectly identified, and 7/157 (4.5%) had a score below the threshold. At a score threshold of Ն1.7, 133/157 (84.7%) isolates were correctly identified, 2/157 (1.3%) isolates were incorrectly identified, and 22/157 (14.0%) isolates were not identified above the threshold. At a score threshold of Ն1.8, 128/157 (81.5%) isolates were correctly identified, no isolates were misidentified, and 29/157 (18.5%) isolates had a score below the threshold. At a score threshold of Ն2.0, 111/157 (70.7%) isolates were correctly identified, no isolates were misidentified, and 46/157 (29.3%) isolates had scores below 2.0.
For the Saramis, 10/157 (6.4%) isolates were not identified at any score in any of the three independent extractions (Table 3) . At a confidence value threshold of Ն80%, 139/157 (88.5%) isolates had a correct identification, 5/157 (3.2%) had an incorrect identification, and 13/157 (8.3%) had an identification below the threshold. At a confidence value cutoff of Ն90%, 134/157 (85.4%) of isolates were correctly identified, 1/157 (0.6%) was incorrectly identified, and 22/157 (14.0%) isolates had a score below the threshold. At a confidence value threshold of Ն95%, 127/157 (80.9%) isolates were correctly identified, 1/157 (0.6%) was incorrectly identified, and 29/157 (18.5%) isolates had a score below the threshold.
For the Vitek MS v3.0, 10/157 (6.4%) isolates were not identified at any score in any of the three independent extractions (Table  3) . At a confidence value threshold of Ն80%, 144/157 (91.7%) isolates had a correct identification, 1/157 (0.6%) isolates had an incorrect identification, and 12/157 (7.6%) isolates had an identification below the threshold. At a confidence value cutoff of Ն90%, 140/157 (89.2%) isolates were correctly identified, 1/157 (0.6%) isolates was incorrectly identified, and 16/157 (10.2%) isolates had a score below the threshold. At a confidence value threshold of 95%, 139/157 (88.5%) of isolates were correctly identified, 1/157 (0.6%) was incorrectly identified, and 17/157 (10.8%) isolates had a score below the threshold. Among the three platforms, there was trend in the frequency of isolates that did not generate an identification after three attempts (P Ͻ 0.11). In a pairwise comparison, there was a trend toward fewer unidentified isolates with Vitek MS v3.0 than with the Biotyper (P Ͻ 0.052) and, to a lesser extent, Saramis (P Ͻ 0.39).
Of the 157 isolates, 15 had a discrepancy between the original identification and the identification obtained on one or more of the three MALDI-TOF MS methods. Definitive identification of these isolates was confirmed by DNA sequencing (Table 4) . Necessity of repeat testing. Next, we compared the numbers of independent extractions, performed on different days, required to obtain a correct identification with score or confidence value cutoffs of Ն1.8, Ն90%, and Ն90% for the Biotyper, Saramis, and Vitek MS v3.0 methods, respectively. For the Biotyper at a score cutoff of Ն1.8, 99/157 (63.1%) isolates were correctly identified to Total  157  29  99  19  10  22  106  11  18  16  121  11  9 a ID, identification.
iments needed for identification at the given threshold (P ϭ 0.040). In a pairwise comparison, the Biotyper performed similarly to Saramis (P Ͻ 0.53) whereas the Biotyper required more runs for identification than Vitek MS v3.0 (P Ͻ 0.012). Saramis showed a trend toward increased numbers of runs needed for identification relative to Vitek MS v3.0 (P Ͻ 0.057).
DISCUSSION
Arguably the most important role of a clinical mycobacteriology laboratory, from both a patient care perspective and a public health perspective, is to differentiate M. tuberculosis from NTM. In addition, current American Thoracic Society/Infectious Diseases Society of America guidelines recommend that "clinically significant NTM isolates should be routinely identified to the species level" (13) . In this study, we compared the Biotyper, Saramis, and Vitek MS v3.0 MALDI-TOF MS methods for the identification of mycobacteria cultivated on solid media. We demonstrated that all three methods provide accurate and reliable identification to the complex and/or species level for the vast majority of mycobacterial clinical isolates. Importantly, all three MALDI-TOF MS methods had 100% accuracy for the identification of the 16 M. tuberculosis complex isolates analyzed in this study. This suggests that MALDI-TOF MS may substitute for current M. tuberculosis identification methods, including those using DNA probes. MALDI-TOF MS is commonly used for routine bacterial identification in clinical laboratories. However, mycobacteria require a protein extraction procedure for organism inactivation and optimal identification. The Biotyper extraction method requires approximately 90 min for preparation of 18 samples compared to approximately 45 min for a similar number of samples using the Vitek MS protocol. Therefore, we assessed whether the extraction methods were interchangeable on the respective platforms. While deviation from each manufacturer's recommended extraction method did not result in misidentifications, it had a negative impact on the frequency of identification and score/confidence values for the Biotyper and Saramis. The Vitek MS v3.0 platform appeared relatively unaffected by the extraction method, at least for the 10 isolates assessed. This emphasizes that clinical samples should be processed using the method used to generate the reference database used for analysis (8) .
Despite the reliability of all three methods to distinguish M. tuberculosis from NTM, a small number of sporadic errors were noted with the various MS methods. All three methods misclassified the one M. parascrofulaceum isolate as M. scrofulaceum. The maximal score for this isolate was 1.7 on Biotyper, while Saramis and Vitek MS v3.0 both reported a maximum confidence value of 99.9%. This isolate was confirmed by 16S rRNA and rpoB gene sequencing (14) , suggesting that current MALDI-TOF MS methods may have difficulty distinguishing M. scrofulaceum and M. parascrofulaceum. Testing of additional related organisms is needed to further characterize this observation.
The Biotyper reproducibly identified two M. smegmatis isolates as M. wolinskyi. However, due to the phylogenetic relationship, all three isolates were classified as belonging to the M. smegmatis group in this study (15) . In addition, the Biotyper reproducibly classified one M. marinum isolate as M. shottsii, which has been reported as a pathogen of striped bass but not as a human pathogen (16) . M. shottsii is nonpigmented, while the isolate tested was pigmented, as is M. marinum, suggesting the possibility of an error in the classification of this entry in the Biotyper reference database. An additional limitation of the Biotyper method was the suboptimal scores for M. chelonae isolates, with only 2/13 identified above a score of Ն1.8. Lowering the score threshold of M. chelonae would have resulted in the clinically significant misclassification of two isolates as M. abscessus and M. immunogenum. Mather et al. previously reported suboptimal identification of M. chelonae by the Biotyper, with only 7/14 isolates correctly identified at a score threshold of Ն2.0 (8). The frequency of correct identification was not affected by the length of cultivation prior to testing (8) . The extraction method and Biotyper RTC software version were the same as those used here, while the mycobacterial reference database differed (8) . In contrast, Balada-Llasat et al. reported correct identification of 23/24 M. chelonae isolates at a score threshold of Ն2.0 (9). The extraction method and mycobacterial database were the same as used here, while the Biotyper RTC software version differed. Therefore, the discrepancies among the three studies may have been due to different software versions, reference databases, or isolate-specific variations or to a combination of these factors.
The Saramis method adequately identified the vast majority of isolates, including all 13 M. chelonae isolates. However, unlike the Biotyper, the Saramis method resulted in no identification for 6/13 M. terrae isolates. Four of these M. terrae isolates were completely unidentified. One of the six isolates was identified as M. fortuitum at a confidence value of 86%. The sixth isolate was identified as two different Gram-positive bacterial species in two independent experiments at scores between 80% and 90%, which would have resulted in the clinical laboratory questioning the identification and commencing troubleshooting steps. Furthermore, at a score cutoff of Ն80%, Saramis misidentified an M. fortuitum isolate and an M. simiae isolate as Streptococcus anginosus and Hanseniaspora guilliermondii, respectively.
Other than the misidentified M. parascrofulaceum isolate, the Vitek MS v3.0 method did not misclassify any isolate at above a score of Ն80%. In addition, while the identification of M. terrae isolates by Vitek MS v3.0 was still suboptimal relative to the Biotyper method, it was improved relative to Saramis. Our panel contained one isolate previously identified as M. mageritense (grouped in the M. smegmatis group in this study) (17) . This isolate was correctly identified by both Biotyper and Saramis, while no identification was provided by Vitek MS v3.0. Testing of other M. mageritense isolates on the Vitek MS v3.0 platform is warranted. Finally, Vitek MS v3.0 was the only method to identify the single M. szulgai isolate examined in this investigation.
This study had a number of strengths. First, we evaluated a diverse and large collection of contemporary clinical isolates, including rare NTM, many of which have not been included in any previously published MALDI-TOF MS identification studies (8, 9, 18) . Second, we directly compared the performances of the Biotyper and Vitek MS instruments. Third, this report represents the first description of the Vitek MS v3.0 platform for identification of Mycobacterium spp. and suggests that the Vitek MS v3.0 may offer modest advantages over the Biotyper and Saramis, especially by reducing the necessity of repeat identification attempts. Finally, we compared commercial mycobacterial reference databases, rather than laboratory-developed databases, which enables generalizability of our findings to other clinical laboratories.
This study had several limitations. First, we assayed only isolates cultivated on solid medium. Second, we did not directly study the impact of organism age on identification. In general, isolates were tested at least once during both "early" and "late" growth. We performed the Biotyper and Vitek MS extractions in parallel, so all isolates were assayed at the same stage of growth on both instrumentation platforms. Third, despite our using a large panel of clinically relevant NTM isolates, rare NTM spp. had different levels of representation based on availability. Further work evaluating a larger number of these rare isolates is needed to definitively assess the reliability of identification by MALDI MS. And finally, multidrug-resistant and extensively drug-resistant M. tuberculosis isolates were not evaluated in this study.
In summary, this study demonstrated that the Biotyper, Saramis, and Vitek MS v3.0 systems can all readily and reliably identify mycobacterial species and that commonly used extraction protocols are adequate for organism inactivation. Implementation of MALDI-TOF MS in the clinical laboratory may decrease turnaround time, labor, and marginal cost per identification relative to current methods.
